Cargando…

不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究

OBJECTIVE: To analyze early hematopoietic response and long-term survival of very severe aplastic anemia (VSAA) patients with different absolute neutrophil counts (ANC) after frontline immnunosuppressive therapy (IST). METHODS: Clinical data and outcome of 145 VSAA patients treated with rabbit antit...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343096/
https://www.ncbi.nlm.nih.gov/pubmed/27093998
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.04.016
_version_ 1783555695355887616
collection PubMed
description OBJECTIVE: To analyze early hematopoietic response and long-term survival of very severe aplastic anemia (VSAA) patients with different absolute neutrophil counts (ANC) after frontline immnunosuppressive therapy (IST). METHODS: Clinical data and outcome of 145 VSAA patients treated with rabbit antithymocyte globulin combined with cyclosporine were retrospectively analyzed. Hematopoietic responses to IST and long-term survival were statistically analyzed for VSAA patients in different ANC subgroups. RESULTS: Pre-IST ANC=0.05×10(9)/L acted as the best cutoff level to predict IST response at 3, 6 months. For 145 VSAA patients, early death rate was 13.4% (11/82) vs 1.6% (1/63), respectively, in the ANC≤0.05×10(9)/L group and ANC>0.05×10(9)/L group (P<0.05). Hematopoietic response rates to IST was 22.0% vs 54.0% (P=0.000) at 3 months, 34.1% vs 63.5% (P=0.000) at 6 months; the overall five-year survival rate was only (62.5±5.4) % vs (91.4±3.7) % (P=0.000) and five-year event-free survival rate was (42.3±5.5) % vs (63.1±6.5) % (P=0.003), respectively, in the ANC≤0.05×10(9)/L group and ANC>0.05×10(9)/L group. CONCLUSION: VSAA patients with extremely low ANC (≤0.05×10(9)/L) had high early death rate and with very low response rate to frontline IST and poor survival, so it is urgent to seek for the alternative frontline therapy that will bring faster and better outcome for these patients.
format Online
Article
Text
id pubmed-7343096
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73430962020-07-16 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To analyze early hematopoietic response and long-term survival of very severe aplastic anemia (VSAA) patients with different absolute neutrophil counts (ANC) after frontline immnunosuppressive therapy (IST). METHODS: Clinical data and outcome of 145 VSAA patients treated with rabbit antithymocyte globulin combined with cyclosporine were retrospectively analyzed. Hematopoietic responses to IST and long-term survival were statistically analyzed for VSAA patients in different ANC subgroups. RESULTS: Pre-IST ANC=0.05×10(9)/L acted as the best cutoff level to predict IST response at 3, 6 months. For 145 VSAA patients, early death rate was 13.4% (11/82) vs 1.6% (1/63), respectively, in the ANC≤0.05×10(9)/L group and ANC>0.05×10(9)/L group (P<0.05). Hematopoietic response rates to IST was 22.0% vs 54.0% (P=0.000) at 3 months, 34.1% vs 63.5% (P=0.000) at 6 months; the overall five-year survival rate was only (62.5±5.4) % vs (91.4±3.7) % (P=0.000) and five-year event-free survival rate was (42.3±5.5) % vs (63.1±6.5) % (P=0.003), respectively, in the ANC≤0.05×10(9)/L group and ANC>0.05×10(9)/L group. CONCLUSION: VSAA patients with extremely low ANC (≤0.05×10(9)/L) had high early death rate and with very low response rate to frontline IST and poor survival, so it is urgent to seek for the alternative frontline therapy that will bring faster and better outcome for these patients. Editorial office of Chinese Journal of Hematology 2016-04 /pmc/articles/PMC7343096/ /pubmed/27093998 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.04.016 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究
title 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究
title_full 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究
title_fullStr 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究
title_full_unstemmed 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究
title_short 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究
title_sort 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343096/
https://www.ncbi.nlm.nih.gov/pubmed/27093998
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.04.016
work_keys_str_mv AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū
AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū